Claritev (NYSE:CTEV – Get Free Report) has been given a consensus rating of “Hold” by the eight ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $34.50.
A number of brokerages have recently issued reports on CTEV. Zacks Research cut Claritev from a “hold” rating to a “strong sell” rating in a research note on Friday, July 17th. Wall Street Zen cut shares of Claritev from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Piper Sandler set a $61.00 target price on shares of Claritev in a report on Wednesday, June 3rd. Barclays started coverage on shares of Claritev in a research report on Friday, April 24th. They set an “overweight” rating and a $28.00 price target on the stock. Finally, Citigroup reiterated a “buy” rating on shares of Claritev in a research note on Wednesday, May 13th.
Get Our Latest Research Report on CTEV
Claritev Stock Down 3.4%
Institutional Investors Weigh In On Claritev
Institutional investors and hedge funds have recently modified their holdings of the company. Arini Captial Management Ltd bought a new position in Claritev during the fourth quarter worth $64,291,000. Public Investment Fund acquired a new position in shares of Claritev in the third quarter valued at $68,009,000. Vanguard Group Inc. bought a new position in shares of Claritev in the third quarter valued at about $27,483,000. Beach Point Capital Management LP raised its position in shares of Claritev by 77.4% in the fourth quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock valued at $32,276,000 after purchasing an additional 329,424 shares during the period. Finally, Nomura Holdings Inc. acquired a new stake in shares of Claritev during the 3rd quarter worth about $7,817,000. 87.15% of the stock is owned by institutional investors.
Claritev Company Profile
Claritev is a healthcare technology, data and insights company focused on improving affordability, transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.
Featured Articles
- Five stocks we like better than Claritev
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
